This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TESARO Announces Presentation Of Niraparib Clinical Data At The 2013 ASCO Annual Meeting

  • Final Phase 1 Results Demonstrate Activity in Ovarian and Breast Cancer
  • Phase 3 Trial in Ovarian Cancer to Begin Enrolling Patients by Mid-Year
  • Phase 3 Trial in Patients With Breast Cancer on Track to Initiate in 2H13

WALTHAM, Mass., May 16, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that final results from a Phase 1 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP), will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. These results include anti-tumor activity and safety data for 100 patients with solid tumors, including 49 patients with high grade serous ovarian cancer (HGSOC) and twelve patients with breast cancer. Full, updated results relating to the abstract will be provided during the investigators' poster presentation on June 4, 2013.

"We are pleased that these data confirm the preliminary results presented at ASCO in 2011, and support advancement of niraparib into Phase 3 trials," stated Dr. Mary Lynne Hedley, President of TESARO. "We remain on track to begin enrolling patients in a Phase 3 trial in the ovarian cancer maintenance setting by mid-year, and to initiate a Phase 3 trial in patients with breast cancer during the second half of 2013."

Investor Briefing

TESARO will host an investor briefing in Chicago on Sunday, June 2 at 6:15 PM local time in conjunction with the ASCO annual meeting. At this briefing, TESARO management will review niraparib clinical data, discuss development plans in ovarian and breast cancer and answer questions from analysts and investors. This event will be webcast live and archived for 30 days at .

ASCO Data Presentation Details

Final Results of the Phase I Trial of Niraparib (MK4827), a Poly(ADP)ribose Polymerase (PARP) Inhibitor Incorporating Proof of Concept Biomarker Studies and Expansion Cohorts Involving BRCA1/2 Mutation Carriers, Sporadic Ovarian and Castration Resistant Prostate Cancer (CRPC), Poster #2513, June 4, 2013 from 8:00 AM to 12:00 PM; 11:30 AM discussion


TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit .

To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters that could affect the availability or commercial potential of our drug candidates. TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO's Form 10-K for the year ended December 31, 2012.
CONTACT: Investor/Media Contact:
         Jennifer Davis
         Sr. Director, Corporate Development & Investor Relations
         +1.781.325.1116 or

TESARO, Inc. Logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.69 -0.59%
FB $119.49 1.43%
GOOG $711.11 1.40%
TSLA $214.93 1.61%
YHOO $37.23 0.79%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs